NCT07087938WithdrawnPhase 1/2
Cannabichromene Safety in Rheumatoid Arthritis
Safety and Behavioral Pharmacology of Cannabichromene as an Adjunct to Rheumatoid Arthritis Treatment; Effects on Inflammatory Markers and Rheumatoid Arthritis Disease Activity
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Reason given: Study did not begin recruiting participants due to insufficient preclinical evidence resulting in FDA clinical hold.
Brief summary (registry, in English)
For this quantitative study, the investigators will collect data on human safety and side-effects of Cannabichromene (CBC) and whether CBC reduces blood inflammatory markers and Rheumatoid Arthritis (RA) disease activity. The participants will participate in an ABAB design with 2 doses of CBC across the A phases. They will attend 5 in-person clinic visits where they will have physical evaluations, complete self-report forms, and have blood drawn for the following tests: hs-CRP, ESR, IL-6, TNF, Complete Blood Count [CBC], and CMP.
- Status (registry)
- Withdrawn
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 31 May 2024
- Start date
- 15 Jul 2028
- Primary completion date
- 31 May 2030
- Lead sponsor
- Crystal Lederhos Smith
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07087938
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has not received stable treatment for at least 1 month prior to the study or is unwilling to continue treatment for the duration of the study
- Is planning a surgery during the course of their participation in the trial
Other illness
- No degree of disease activity present at research study intake (determined by research study personnel)
Age
- Under age 21
Other
- Do not have a current diagnosis of RA
- Unable to read and speak English, or provide written consent
- Are currently pregnant or planning to become pregnant during the course of the trial
- Unwilling to use a form of birth control during the duration of the study
- Unwilling to refrain from cannabis use (other than study provided CBC) over the course of the study
Who the study is looking for
- Have a current diagnosis of RA
- Having stable treatment for at least 1 month prior to the study and being willing to continue that treatment for the duration of the study
- Having some degree of disease activity present at research study intake (determined by research study personnel)
- Aged 21+
- Able to read and speak English, and provide written consent
- Not currently pregnant or planning to become pregnant during the trial
- Not currently planning any surgeries during the course of the trial
- Willing to use a form of birth control for the duration of the study (all participants will be required to use birth control for the duration of the study)
- Willing to refrain from cannabis use (other than study provided CBC) over the course of the study
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington State University | Spokane | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.